Header Logo

Connection

Lynn Morris to Adult

Back to Details
This is a "connection" page, showing publications Lynn Morris has written about Adult.
Lynn Morris
Connection Strength
1,303
Adult
  1. HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. PLoS One. 2020; 15(6):e0234937.
    View in: PubMed
    Score: 0,080
  2. Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. mSphere. 2020 Jan 29; 5(1).
    View in: PubMed
    Score: 0,078
  3. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. PLoS Pathog. 2019 12; 15(12):e1008064.
    View in: PubMed
    Score: 0,078
  4. Evidence for both Intermittent and Persistent Compartmentalization of HIV-1 in the Female Genital Tract. J Virol. 2019 05 15; 93(10).
    View in: PubMed
    Score: 0,074
  5. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes. J Virol. 2018 09 01; 92(17).
    View in: PubMed
    Score: 0,071
  6. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. PLoS Pathog. 2018 04; 14(4):e1006987.
    View in: PubMed
    Score: 0,069
  7. Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire. J Immunol. 2015 May 01; 194(9):4371-8.
    View in: PubMed
    Score: 0,056
  8. Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. Antivir Ther. 2013; 18(7):915-20.
    View in: PubMed
    Score: 0,049
  9. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010 Jul 17; 24(11):1679-87.
    View in: PubMed
    Score: 0,040
  10. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology. 2010 Jun 20; 402(1):187-96.
    View in: PubMed
    Score: 0,040
  11. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008 Nov; 24(11):1449-54.
    View in: PubMed
    Score: 0,036
  12. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther. 2008; 13 Suppl 2:101-7.
    View in: PubMed
    Score: 0,034
  13. Use of alternate coreceptors on primary cells by two HIV-1 isolates. Virology. 2005 Aug 15; 339(1):136-44.
    View in: PubMed
    Score: 0,029
  14. Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern. Sci Rep. 2025 Feb 14; 15(1):5549.
    View in: PubMed
    Score: 0,028
  15. Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. AIDS Res Hum Retroviruses. 2005 Jan; 21(1):103-9.
    View in: PubMed
    Score: 0,028
  16. Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. AIDS. 2003 Jul 25; 17(11):1698-700.
    View in: PubMed
    Score: 0,025
  17. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol. 2003 Apr; 77(7):4449-56.
    View in: PubMed
    Score: 0,024
  18. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med. 2021 03 18; 384(11):1003-1014.
    View in: PubMed
    Score: 0,021
  19. Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. Clin Infect Dis. 2021 01 23; 72(1):50-60.
    View in: PubMed
    Score: 0,021
  20. Phylogenetic analysis of human herpesvirus-8 in South Africa and identification of a novel subgroup. J Gen Virol. 2000 Aug; 81(Pt 8):2029-2038.
    View in: PubMed
    Score: 0,020
  21. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Med. 2020 05; 17(5):e1003117.
    View in: PubMed
    Score: 0,020
  22. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020 02; 17(2):e1003038.
    View in: PubMed
    Score: 0,020
  23. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 09 18; 11(510).
    View in: PubMed
    Score: 0,019
  24. Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods. Antivir Ther. 2019; 24(3):203-210.
    View in: PubMed
    Score: 0,018
  25. HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. Cell Host Microbe. 2018 10 10; 24(4):593-599.e3.
    View in: PubMed
    Score: 0,018
  26. High-Frequency, Functional HIV-Specific T-Follicular Helper and Regulatory Cells Are Present Within Germinal Centers in Children but Not Adults. Front Immunol. 2018; 9:1975.
    View in: PubMed
    Score: 0,018
  27. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018 07; 5(7):e366-e378.
    View in: PubMed
    Score: 0,017
  28. Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa. J Antimicrob Chemother. 2017 Nov 01; 72(11):3141-3148.
    View in: PubMed
    Score: 0,017
  29. Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. PLoS One. 2016; 11(9):e0161753.
    View in: PubMed
    Score: 0,015
  30. Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol. 2016 06; 23(6):496-506.
    View in: PubMed
    Score: 0,015
  31. Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage. PLoS One. 2015; 10(7):e0131906.
    View in: PubMed
    Score: 0,014
  32. Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia. J Acquir Immune Defic Syndr. 2015 Apr 01; 68(4):463-71.
    View in: PubMed
    Score: 0,014
  33. Rapid disease progression in HIV-1 subtype C-infected South African women. Clin Infect Dis. 2014 Nov 01; 59(9):1322-31.
    View in: PubMed
    Score: 0,013
  34. Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study. Trop Med Int Health. 2014 Feb; 19(2):236-9.
    View in: PubMed
    Score: 0,013
  35. Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial. J Infect Dis. 2014 Jun 15; 209(12):1916-20.
    View in: PubMed
    Score: 0,013
  36. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. J Infect Dis. 2014 Mar 01; 209(5):711-20.
    View in: PubMed
    Score: 0,012
  37. Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology. 2012 Nov 25; 433(2):410-20.
    View in: PubMed
    Score: 0,012
  38. Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):304-8.
    View in: PubMed
    Score: 0,011
  39. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011 Mar 09; 6(3):e17518.
    View in: PubMed
    Score: 0,011
  40. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. BMC Public Health. 2011 Feb 08; 11:88.
    View in: PubMed
    Score: 0,010
  41. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 03; 329(5996):1168-74.
    View in: PubMed
    Score: 0,010
  42. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009 Dec 15; 49(12):1928-35.
    View in: PubMed
    Score: 0,010
  43. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. AIDS. 2009 Apr 27; 23(7):809-16.
    View in: PubMed
    Score: 0,009
  44. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009 Feb 15; 48(4):462-72.
    View in: PubMed
    Score: 0,009
  45. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS. 2008 Jul 11; 22(11):1333-43.
    View in: PubMed
    Score: 0,009
  46. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One. 2008 Apr 16; 3(4):e1954.
    View in: PubMed
    Score: 0,009
  47. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology. 2007 Nov 10; 368(1):172-81.
    View in: PubMed
    Score: 0,008
  48. Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr. 2007 Jun 01; 45(2):206-9.
    View in: PubMed
    Score: 0,008
  49. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2007 Feb 01; 44(2):148-53.
    View in: PubMed
    Score: 0,008
  50. Does tuberculosis increase HIV load? J Infect Dis. 2004 Nov 01; 190(9):1677-84.
    View in: PubMed
    Score: 0,007
  51. Human herpesvirus-8 antibodies and DNA in HIV-1 infected patients in South Africa. Epidemiol Infect. 2003 Dec; 131(3):1125-9.
    View in: PubMed
    Score: 0,006
  52. Meningitis in a community with a high prevalence of tuberculosis and HIV infection. J Neurol Sci. 1999 Jan 01; 162(1):20-6.
    View in: PubMed
    Score: 0,005
  53. Dual infective pathology in patients with cryptococcal meningitis. Neurology. 1998 Oct; 51(4):1213-5.
    View in: PubMed
    Score: 0,004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.